Hartford Courant

Supreme Court to hear case on abortion drug use, access

- By Mark Sherman

WASHINGTON — The Supreme Court will again wade into the fractious issue of abortion this week when it hears arguments over a medication used in the most common way to end a pregnancy.

The mifepristo­ne case has implicatio­ns for millions of women no matter where they live in America and, perhaps, for the race for the White House.

Two years after the Supreme Court overturned Roe v. Wade and cleared the way for bans or severe restrictio­ns on abortion in many Republican-led states, abortion opponents will ask the high court Tuesday to ratify a ruling from a conservati­ve federal appeals court that would limit access to mifepristo­ne, which was used in nearly two-thirds of all abortions in the United States last year.

That decision to reverse Roe had immediate political consequenc­es, with Democrats making the case that the court had taken away a right that women held for half a century and winning elections as a result. Even conservati­ve-leaning states like Kansas and Ohio voted against abortion restrictio­ns.

By rolling back Food and Drug Administra­tion changes to the use of mifepristo­ne, the ruling would cut off access to the drug through the mail and impose other restrictio­ns, even in states where abortion is legal. The restrictio­ns would shorten the time when mifepristo­ne can be used in pregnancy, to seven weeks from 10 currently.

Most adults in the U.S., 55%, believe medication abortion pills are very or somewhat safe when taken as directed by a doctor, according to a KFF poll from May 2023, and 65% have “a lot” or “some” confidence in the FDA to ensure that medication­s sold in the U.S. are safe and effective.

A decision should come by late June. But no matter the outcome, the Supreme Court has not seen its last abortion case. Legal battles are pending over state restrictio­ns, and new federal limits are likely if former President Donald Trump, the Republican­s’ presumptiv­e nominee for 2024, returns to the White House.

Next month, the justices will hear arguments over whether a federal law on emergency treatment at hospitals must include abortions, even in states that have otherwise banned them.

Mifepristo­ne, made by New York-based Danco Laboratori­es, is one of two drugs, along with misoprosto­l, used in medication abortions. Their numbers have been rising for years, and they accounted for 63% of the 1 million-plus abortions in the U.S. last year, according to an estimate by the Guttmacher Institute, which supports abortion rights. More than 5 million people have used mifepristo­ne since 2000.

Mifepristo­ne is taken first to dilate the cervix and block the hormone progestero­ne, which is needed to sustain a pregnancy. Misoprosto­l is taken 24 to 48 hours later, causing the uterus to contract and expel pregnancy tissue.

Health care providers have said that if mifepristo­ne is no longer available or is too hard to obtain, they would switch to using only misoprosto­l, which is somewhat less effective in ending pregnancie­s.

Underscori­ng the importance of the case, the number of medication abortions is rising. Taking pills at home to end a pregnancy is less invasive than surgery, more convenient than having to travel to an abortion clinic and more private, allowing women to avoid abortion protesters who picket clinics.

It’s becoming even easier to get the two drugs in some states now that CVS and Walgreens announced pilot programs to dispense the pills at their pharmacies.

For women living in states with abortion bans or restrictio­ns, mail-order delivery may be their only practical option, said Julie Kay, executive director of the Abortion Coalition for Telemedici­ne.

The medication is sent by providers in states that have laws meant to shield them from any legal trouble for working with people who live in states that don’t permit medication abortions. The pills cost $150 and usually arrive within three to five days, Kay said.

 ?? ALLEN G. BREED/AP 2022 ?? The Supreme Court will hear arguments Tuesday about access to mifepristo­ne, shown at West Alabama Women’s Center in Tuscaloosa, Alabama.
ALLEN G. BREED/AP 2022 The Supreme Court will hear arguments Tuesday about access to mifepristo­ne, shown at West Alabama Women’s Center in Tuscaloosa, Alabama.

Newspapers in English

Newspapers from United States